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Abstract
The 14-3-3 proteins are a family of regulatory signaling molecules that interact with other proteins in a phosphorylation-
dependent manner and function as adapter or scaffold proteins in signal transduction pathways. One family member, 14-3-
3f, is believed to function in cell signaling, cycle control, and apoptotic death. A systematic proteomic analysis done in our
laboratory has identified signal transducers and activators of transcription 3 (Stat3) as a novel 14-3-3f interacting protein.
Following our initial finding, in this study, we provide evidence that 14-3-3f interacts physically with Stat3. We further
demonstrate that phosphorylation of Stat3 at Ser727 is vital for 14-3-3f interaction and mutation of Ser727 to Alanine
abolished 14-3-3f/Stat3 association. Inhibition of 14-3-3f protein expression in U266 cells inhibited Stat3 Ser727
phosphorylation and nuclear translocation, and decreased both Stat3 DNA binding and transcriptional activity. Moreover,
14-3-3f is involved in the regulation of protein kinase C (PKC) activity and 14-3-3f binding to Stat3 protects Ser727
dephosphorylation from protein phosphatase 2A (PP2A). Taken together, our findings support the model that multiple
signaling events impinge on Stat3 and that 14-3-3f serves as an essential coordinator for different pathways to regulate
Stat3 activation and function in MM cells.
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Introduction
The 14-3-3 proteins are a family of highly conserved,
ubiquitously expressed regulatory molecules and seven isoforms,
designated d, g, c, e, h, b and f, have been described previously
[1,2]. The 14-3-3 proteins are known for their ability to bind a
plethora of client proteins, mostly through a phosphorylated
serine or threonine motif [3,4]. Because 14-3-3 interactions are
primarily phosphorylation- dependent, the 14-3-3 proteins have
been tightly integrated into the central phosphor-relay regulatory
pathways that form the core of vital signal transduction
pathways. Through regulated interactions with crucial signaling
mediators, 14-3-3 controls diverse cellular responses ranging
from signal transduction, cell cycle progression, metabolism,
oncogenesis and apoptosis [5]. The 14-3-3 proteins have raised
to a position of integrators of diverse signaling cues that impact
cell fate and cancer development [5]. In general, 14-3-3 proteins
play a role in promoting survival and repressing apoptosis [6].
However, individual 14-3-3 proteins may have unique functions
in certain physiological contexts and might selectively affect
distinct aspects of the carcinogenic process [7]. Especially,
involvement of 14-3-3f in multiple signaling pathways has been
reported and activities of various signaling mediators are
differentially regulated by 14-3-3f via direct physical association
[8]. However, whether 14-3-3f also regulates the signal
transducers and activators of transcription (Stat) family was
unknown. In the course of our search for proteins that interact
with 14-3-3f, for the first time, we found that Stat3 is one of the
novel 14-3-3f interacting proteins [9].
The Stat proteins are a conserved family of transcription
factors implicated in regulating processes such as inflammation,
survival, proliferation, metastasis, angiogenesis, and chemoresis-
tance of tumor cells [10]. One of these members, namely Stat3,
is ubiquitously expressed and is functionally involved in
regulating cell proliferation, differentiation and cell survival
[11]. In many cancer cells, Stat3 signaling has been recognized
as a pivotal pathway supporting survival and growth [12,13,14].
Stat3 is often constitutively active in many human cancer cells
including multiple myeloma (MM), leukemia, lymphoma, and
solid tumors [12,15]. The Stat3 signaling is modulated, both
positively and negatively, by its interaction with numerous other
proteins, and crosstalk occurs with various other signaling
cascades, including the NF-kB, AP-1 or PI-3K pathways [16].
We made the hypothesis that the physiological interaction
between 14-3-3f with Stat3 might contribute to the cooperation
and/or coordination of their functions in the control of
numerous intracellular signaling and regulatory pathways in
MM cells.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29554The purpose of the present study was to further elucidate the
molecular mechanisms underlying the regulation of Stat3 pathway
and to contribute to a better understanding of the cross-talk
between 14-3-3f and Stat3 signaling in MM cells. In this study,
evidence is provided that 14-3-3f interacts with Stat3 in a
phosphorylation-dependent manner and the phosphorylated
Ser727 is necessary for 14-3-3f binding. Of note, 14-3-3f is
required for nuclear translocation, optimal DNA-binding and
transcriptional activity of Stat3. Furthermore, our results indicated
that 14-3-3f is involved in the regulation of PKC activity and
protection of Ser727 dephosphorylation from protein phosphatase
2A (PP2A) in U266 cells. Thus, our findings have important
implications in the understanding of the mechanisms that regulate
Stat3 activity and function in MM cells.
Results
14-3-3f Interacts with Stat3 Protein
We had previously reported an interaction between 14-3-3f and
Stat3 in U266 cells [9]. We further confirm this association
between endogenously expressed proteins by using reciprocal
immunoprecipitation. As shown in Figure 1A, Stat3 was detected
in the 14-3-3f immune complex and the U266 cell lysate (Input)
but not in the normal rabbit IgG control (Ctr). Furthermore,
reverse immunoprecipitation assay using specific antibodies for
Stat3 followed by Western blotting with 14-3-3f confirmed their
binding to 14-3-3f. Thus, compelling evidence shows that 14-3-3f
interacts with Stat3 in U266 cells. Seven 14-3-3 isoforms are
expressed in U266 cells [9]. To determine whether Stat3 also
interacts with other 14-3-3 isoforms, U266 cell lysates were
immunoprecipitated using 14-3-3 isoform specific antibodies [9]
and the co-precipitated Stat3 was detected by Western blot. The
results showed absence of binding to rabbit IgG control (Ctr) and
14-3-3d, g; weak binding to c, e, h; moderate binding to b and
strong binding to f (Fig. 1B). We have shown that several 14-3-3
isoforms (14-3-3b, e, c, g, h) were co-purified with 14-3-3f [9],
which is in accordance with previous reports showing hetero-
dimerization between different 14-3-3 isoforms [17,18]. Therefore,
our results demonstrated that Stat3 can interact with 14-3-3f
directly and also suggested that Stat3 can bind with other
mammalian 14-3-3 isoforms in a redundant manner or through
binding to 14-3-3f.
Figure 1. 14-3-3f is a Stat3-interacting protein. (A) Immunoprecipitation assays of 14-3-3f and Stat3 proteins were carried out in U266 cells as
described in Materials and Method section. No band of Stat3 was observed in the IgG negative control (Ctr). (B) Interaction of Stat3 with 14-3-3
isoforms. (C) Schematic illustration of Stat3 domains and their truncations. ND: N-terminal domain, CC: coiled-coil domain, DBD: DNA binding domain,
LD: linker domain, SH2: SH2 domain and CT: C-terminal. (D) Identification of the Stat3 domains interacting with 14-3-3f. Myc-Stat3 domain truncation
mutants were transfected with HA-14-3-3f in U266 cells. An empty vector was used as a control. Anti-HA immunoprecipitates were analyzed by
Western blot with antibodies to Myc (upper panel) or HA (middle panel). The expression of Myc-Stat3 is shown in the bottom panel. (E) Stat3 C-
terminal mutants binding to 14-3-3f. Experiments were performed in triplicate and representative data are shown.
doi:10.1371/journal.pone.0029554.g001
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To identify which region of Stat3 is involved in this interaction,
we generated Stat3 truncated mutants, successively deleting Stat3
domains from the C terminus (Fig. 1C), and analyzed their ability to
interact with 14-3-3f. These truncated Stat3 constructs were
transfected with 14-3-3f into U266 cells. Co-IP experiments
revealed that Stat3 C-terminal region (amino acids 688 to 770)
retained 14-3-3f interaction whereas all other truncated mutants
failed to co-IP with 14-3-3f (Fig. 1D). These results indicate that the
C-terminal tail of Stat3 is responsible for interaction with 14-3-3f.
Serine 727 of Stat3 Is Essential for 14-3-3f Binding
A major function of 14-3-3 proteins is to bind to proteins with
phosphorylated serine and threonine residues [19,20,21]. Since we
had demonstrated an association between C-terminal region
(amino acids 688 to 770) of Stat3 and 14-3-3f, we wanted to
determine whether the association between Stat3 and 14-3-3
proteins required phosphorylation. Mass spectrometric analysis
identified several phosphorylation sites on the C-terminal tail of
Stat3, including S691 [22], T714 [23,24], T717 [24], S719 [25]
and S727 [26,27,28,29]. To find the phosphorylation site that is
involved in binding to 14-3-3f, myc-Stat3 (688–770) or mutants
(S691A, T714A, T717A, S719A and S727A) plasmids were
generated and transfected into U266 cells, along with the HA-14-
3-3f plasmids. Total cell lysates were analyzed by anti-HA IP
followed by myc Western blot. The results showed that Stat3
binding to 14-3-3f was abrogated by the S727A mutation (Fig. 1E).
These results suggested that phsophorylated Ser727 (pSer727) is
the major binding site for 14-3-3f.
Modeling of the 14-3-3f/Stat3 Complex Allows
Rationalization of the Results
To rationalize our results we analyzed the structures of the 14-3-
3f/Stat3 complex. A number of 14-3-3f-partner (most are short
peptides) complex structures were solved and available in the PDB
database (Table S1). In the complex structures, partners
interacting with 14-3-3f contain phsophorylated serine or
threonine, which bind to positive charged residues R56 and
R127, and R60 of 14-3-3f. So R56, R127 and R60 are supposed
to be the possible binding sites of the pSer727 of Stat3. In all the
14-3-3f partner peptides listed in Table S1, a positive charged
residue (R or K) which is 1-3 residues away in the N-terminal
direction from the phsophorylated site is found. This positive
residue is proposed to interact with the phsophorylated site too,
helping to stabilize the interaction of 14-3-3f R56, R127 and R60
with the phsophorylated site. Stat3 is different to all the above
peptides as its positive residue (R) is in the C-termical direction
from the phsophorylated site (pSer727). For simplicity of MD
simulation, we used a 17-peptide (CSNTIDLPMpSPRTLD SL) of
Stat3 (referred to as Stat3 peptide in the following text) that is
critical for the binding to represent Stat3. We constructed the
starting structure of the Stat3 peptide by residue mutation using
1IB1 as template and then MD simulations with AMBER10
program were carried out to simulate the interaction between 14-
3-3f and Stat3 peptide with phsophorylated Ser727 (referred to as
pSer727 Stat3 peptide in the following text). After more than 24 ns
simulation, the system balanced and the key residue pSer727, form
four stable salt bridges with R56, R60, R127 of 14-3-3f and with
R729 of Stat3 peptide itself. All distances between the arginine CZ
atoms and the pSer727 phosphorous atom are nearly 4 A ˚ (Fig. 2A
and 2B). Then the 24 ns structure was stripped from the MDs
trajectory as the starting geometry for further simulations. A 14-3-
3f/Stat3 peptide complex was constructed by dephosphorylation
of the pSer727 of the 14-3-3f/pSer727 Stat3 peptide complex.
Both 14-3-3f/Stat3 peptide complex and 14-3-3f/pSer727 Stat3
peptide complex were subject to further MD simulations. The
further MD simulations show that without phsophorylated Ser727
Stat3 peptides moves away from the binding region (Video S1).
The interaction energies of 14-3-3f with Stat3 peptide and
pSer727 Stat3 peptide are shown in Figure 2C. After 24 ns
simulations the interaction energy of 14-3-3f with pSer727 Stat3
peptide (about 280 KCal/mol) is more than three times lower
than that with Stat3 peptide (about 220 KCal/mol), which means
a significant binding affinity decrease after Ser727 dephsophoryla-
tion. The Stat3 peptide also moves away from the interaction
region for about 6.5 A ˚ to 22.8 A ˚ (Fig. 2D). Notably, for most of
the simulation time, pSer727 and R729 of Stat3 peptide are
combined together, which proved our previous suppose that R729
helps to stabilize the interaction of 14-3-3f’s R residues with
pSer727.
14-3-3f regulates Stat3 transcriptional activity via Ser727
Stat3 is constitutively activated in U266 cells [12] and various
primary tumors and tumor cell lines [30]. Transcriptional activity
of Stat3 is controlled by phosphorylation on Ser727 and Tyr 705,
followed by dimerization and nuclear translocation. Evidence
indicates that cooperation of both tyrosine and serine phosphor-
ylations is necessary for full activation of Stat3 [30,31]. To
investigate the level of Stat3 signaling the 14-3-3f acts on, we
studied whether 14-3-3f knockdown interferes with activation of
Stat3, that is, phosphorylation of tyrosine 705 and serine 727. In
our previous work, we developed the 14-3-3f knockdown U266
cell line (U266-KD) and its negative control cell line (U266-NC)
[9]. As shown in Figure 3A, compared with parental U266 and
U266-NC cells, Stat3 phosphorylation at S727 was clearly
inhibited by 14-3-3f depletion, meanwhile phosphorylation at
Y705 and total Stat3 protein levels were not affected. Our results
prompted us to further investigate the effects of overexpression of
14-3-3f in U266 cells. We transiently transfected U266-KD,
U266-NC and parental U266 cells with an expression vector
containing a cDNA encoding human 14-3-3f or a blank vector as
a control. The overexpression of 14-3-3f was confirmed by
Western blotting (Fig. 3A). As shown in Figure 3A, compared with
the cells transfected with the control vector, transient expression of
14-3-3f increased the Stat3 phosphorylation at S727 in U266-KD
cells. The results showed that 14-3-3f knockdown inhibited S727
phosporylation of Stat3. Because phosphorylation causes dimer-
ization of Stat3 and then nuclear translocation [12], we therefore
next studied whether 14-3-3f knock down might influence this
translocation process by immunocytochemistry. In U266 cells,
Stat3 preferentially localized to the nucleus, as apparent by
Hoechst staining (Figure 3B). Depletion of 14-3-3f prevented
nuclear translocation of Stat3, as was expected from its inhibitory
effect on phosphorylation of Stat3 (Fig. 3B). When Stat3 is
translocated to the nucleus, it binds to the DNA, an event that in
turn regulates gene transcription [12]. Therefore, we monitored
the activity of Stat3 dimers inside the nucleus by assessing the
Stat3 DNA binding ability in the presence or absence of 14-3-3f.
Relative expression of Stat3 was determined using image
densitometry. As shown in Figure 3C, the DNA-binding ability
of Stat3 in the U266-KD cells was significantly reduced (Fig. 3C,
lane 4). With the overexpression of 14-3-3f, the DNA-binding
ability of nuclear Stat3 was increased significantly in the U266-KD
cells (Fig. 3C, lane 7). These data indicate that 14-3-3f is required
for optimal DNA binding of Stat3 to its DNA response element.
Next, we further measured the effects of 14-3-3f on Stat3 activity
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down of 14-3-3f in U266 cells yielded a significant decrease in the
Stat3-dependent relative luciferase activity, while overexpression
of 14-3-3f markedly enhanced Stat3-mediated transcriptional
activity in U266-KD cells. Taken together, these data suggest that
14-3-3f positively regulates the transcriptional activity of Stat3 and
is necessary for Stat3-mediated transcriptional activation in U266
cells.
PKC activity is compromised in the absence of 14-3-3f
It is well established that 14-3-3 proteins function as a protein
kinase C (PKC) regulator [32,33,34,35] and 14-3-3f activates
PKC in vitro [36,37]. Recently, evidence indicates that PKC
interacts with Stat3, phosphorylates Stat3 Ser727, and increases
both DNA-binding and transcriptional activity of Stat3 [38].
Therefore, we speculated that 14-3-3f might affect Stat3 activation
via regulating the PKC activity. In MM, PKC isoform expression
has been reported in several MM cell lines [39,40,41]. Specifically,
our results show high expression of PKC a, PKC d and PKC f;
low expression of PKCi, PKC b, PKC m and PKC e; and absence
of PKC h and PKC c in U266-NC, U266-KD cells and its parent
U266 cell line (Fig. 4A). We therefore focus on PKC a, PKC d and
PKC f. We investigated whether 14-3-3f knock down affects PKC
activity in U266 cells using immunoprecipitation kinase assays. As
shown in Figure 4B–D, knockdown of 14-3-3f resulted in a
significant decrease in the kinase activities of PKC a, PKC d and
PKC f (p,0.05), whereas the amount of PKCs that was used in
each experimental condition was similar, as determined by
immunoblotting with specific PKC isoform antibodies. With the
overexpression of 14-3-3f, the kinase activities of PKC a, PKC d
and PKC f were increased significantly in the U266-KD cells
(p,0.05), compared with the cells transfected with the control
Figure 3. Effect of 14-3-3f knock down on Stat3 activity. (A) Effect of 14-3-3f knock down on Stat3 activity in U266 cells. U266, 14-3-3f
knockdown U266 cell line (U266-KD) and its negative control cell line (U266-NC) cells were transfected with 14-3-3f plasmid or blank vector.
Phosphorylation of Stat3 Tyr705 and Ser727 was detected by the specific anti-phospho-Tyr705 and anti-phospho-Ser727 antibodies, and the blot was
stripped and reprobed with anti-Stat3 antibody. The blot was also probed by GAPDH antibody to serve as loading controls. (B) Influence of 14-3-3f
knock-down on Stat3 nuclear translocation. The subcellular localization of Stat3 in U266-NC and U266-KD cells was monitored by using fluorescence
microscopy. (C) 14-3-3f knock down inhibits constitutively active Stat3 in U266 cells. U266, U266-NC and U266-KD cells were transfected with 14-3-3f
plasmid or blank vector as indicated. Nuclear extracts prepared from these cells were incubated with hSIE probe and analyzed by EMSA. Lane 1 (C1),
hSIE oligonucleotide only; lane 8 (C2), U266 nuclear extracts+1006excess unlabeled hSIE oligonucleotide. Relative expression of Stat3 (normalized to
U266 samples) was determined using image densitometry. (D) Reporter constructs were cotransfected into U266, U266-NC and U266-KD cells
together with expression vectors encoding 14-3-3f or blank vector as indicated. Luciferase activity in the cells was analyzed by dual-luciferase assay.
*Significantly different compared to the U266 and U266-NC cells (p,0.01). **Significantly different compared to U266-KD cells transfected with blank
vector (p,0.01). Experiments were performed in triplicate and representative data are shown.
doi:10.1371/journal.pone.0029554.g003
Figure 2. Structural models of 14-3-3f in complex with Stat3. (A–B) The crucial amino acids of 14-3-3f interacting with phosphorylated Stat3
peptide. Distance of the zeta carbon atoms of R56, R60, and R127 of 14-3-3f between the phosphorus atom of the phosphorylated Stat3 peptide
after 24 ns MD simulations of balance were shown. (C) Binding free energy change and the structural movements of the Stat3 peptide after
dephosphorylation. Differences of the binding free energies of 14-3-3f with phosphorylated and dephosphorylated Stat3 peptides. (D) Starting
geometry of dephosphorylated Stat3 peptide (purple), and the dissociated dephosphorylated Stat3 peptide after 24 ns MD simulation (green). The
14-3-3f is shown in cyan.
doi:10.1371/journal.pone.0029554.g002
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involved in the regulation of PKC activity in U266 cells.
14-3-3f Proteins Protect Stat3 phosphorylation at S727
from PP2A Activity
It has been reported that 14-3-3 can protect phosphorylated
proteins from access by the catalytic unit of the protein phosphatase
2A (PP2A) thus preventing its dephosphorylation [42]. Therefore,
we hypothesized that binding of 14-3-3f to Ser727 of Stat3 protects
it from phosphatase activity. To test this hypothesis, we used a
nonphosphorylatedpeptide, R18, which has been shown to displace
14-3-3 from its phosphorylated binding partners [43,44]. As
predicted, the R18 peptide efficiently displaced 14-3-3f from Stat3
(Fig. 5A). Lysates containing phosphorylated Myc-Stat3 were then
subjected to an in vitro dephosphorylation assay in a buffer
compatible with phosphatase but not kinase activity. As shown in
Figure 5B, S727 was dephosphorylated when 14-3-3f was displaced
by R18, suggesting the presence of an active phosphatase (s).
Dephosphorylation of Y705, site not implicated in 14-3-3f binding,
was unaffected by R18 (Fig. 5B). Because previous data suggest that
PP2A is the predominant Ser/Thr phosphatase that interacts with
Stat3 [45], we addressed its contribution to Ser727 dephosphory-
lation in cell-free extracts containing FST, a selective inhibitor of
PP2A [46]. In the presence of R18, FST inhibited dephosphory-
lation of Stat3 at S727 in a dose-dependent manner (Fig. 5C). To
demonstrate that PP2A has the capacity to directly dephosphorylate
Stat3, we performed an in vitro phosphatase assay. As shown in
Figure 5D, increasing amounts of purified PP2A effectively
Figure 4. Effects of 14-3-3f on PKC activity. (A) PKC isoform expression in U266, U266-NC and U266-KD cells. Cell lysates from rat brain were
used as a positive control for PKC expression. (B–D) 14-3-3f knock down inhibits PKC isoform kinase activity. PKC isoform activity was determined
using PKC immunoprecipitation kinase assays. After transfected with 14-3-3f plasmid or blank vector as indicated, equal amounts of whole-cell
lysates were immunoprecipitated with PKC a (B), PKC d (C) and PKC f (D) antibodies and immunoblotted with indicated antibodies. IP indicates
immunoprecipitation; Ctr, immunoprecipitation with protein A/G Plus beads, whole-cell lysates, and preimmune rabbit serum. *Significantly different
compared to the U266 and U266-NC cells (p,0.05). **Significantly different compared to U266-KD cells transfected with blank vector (p,0.05).
Experiments were performed in triplicate and representative data are shown.
doi:10.1371/journal.pone.0029554.g004
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suggest that the association between Stat3 and 14-3-3f protects
S727 dephosphorylation from PP2A.
Discussion
Stat3 activity is tightly regulated by its interacting proteins and
multiple signaling cascades and its prolonged activation is
associated with various malignancies, including MM [12,47]. In
this study, we reported a novel interaction between 14-3-3f and
Stat3 in myeloma cells. Through the use of multiple biochemical
approaches, we demonstrated that 14-3-3f is a bona fide Stat3
interacting partner in U266 cells. Phosphorylation of the Ser727
residue in the C terminus of Stat3 mediates the Stat3/14-3-3f
interaction, and replacement of this crucial residue with
phosphorylation-resistant Alanine totally abolishes the protein
associations (Fig. 1E). Based on these results, it is possible that 14-
3-3f interacts only with Ser727-phosphorylated Stat3 in U266
cells. The Stat3/14-3-3f interaction leads to an increase of the
endogenous Stat3 transcriptional activity, whereas the absence of
14-3-3f leads to significant impairment in Stat3 activity (Fig. 3).
These results suggest that 14-3-3f is a positive regulator of Stat3
activity. Generally, in addition to the phosphorylation of Tyr705,
phosphorylation of the Ser727 residue also contributes to the
activation of Stat3. While tyrosine phosphorylation plays a key role
in all the basic events required for Stat3 activation, such as dimer
formation, nuclear translocation and DNA binding, serine
phosphorylation is required for its maximal transcriptional
activity. Serine phosphorylation, therefore, probably represents a
second level in the regulation mechanism through which, with the
assistance of 14-3-3f, maximal Stat3 transcriptional activity is
achieved. 14-3-3f may, in fact, serve as a molecular stabilizer,
specifically devoted to serine phosphorylation, by converting Stat3
from its ‘primarily activated’ form to ‘optimally activated’ form.
This second stage of regulation may involve various events such as
enhanced Stat3 DNA binding and coactivator recruitment.
Identification of Stat3/14-3-3f interaction via the Ser727 residue
also provides a potential explanation for the long-undetermined
mechanism of the serine phosphorylation-mediated enhancement
to Stat3 transcription.
Importantly, it is well established that 14-3-3 proteins are
involved in various steps regulating the Stat3 activity, including
PKC [32,33,34,35], Raf1 [48,49], MEK1/2 [50], and PP2A [42].
Consistent with these reports, our results demonstrated that 14-3-
3f is involved in the regulation of PKC activity (Fig. 4) and the
association between Stat3 and 14-3-3f protects Ser727 dephos-
phorylation from PP2A (Fig. 5). These data, along with the results
on Stat3/14-3-3f interaction, support the model that multiple
signaling events, including PKC, Raf1, MEK1/2, ERK1/2 and
PP2A, impinge on Stat3 and that 14-3-3 proteins serve as an
essential coordinator for different pathways to regulate Stat3
activity in myeloma cells (Fig. 6). As shown in Figure 6, 14-3-3f is
linked to constitutive activation of Stat3 in myeloma cells. 14-3-3f
and Stat3, the proteins with oncogenic traits, are important
components of development and maintenance of MM.
Recently, 14-3-3f has been identified as a prognostic marker
and therapeutic target for multiple tumor types [5]. We also
reported that inhibition of 14-3-3f decreases the activity of some
pathways of the MM signaling network and induces apoptosis in
MM cells [51]. Therefore, 14-3-3f contributes to the maintenance
of the MM survival network and pharmacologic inhibition of 14-3-
3f could be an interesting approach to develop novel therapies for
MM. However, targeting 14-3-3f may be challenging at the
current stage because 14-3-3f regulates many important proteins
that are essential for homeostasis. Based on our findings that 14-3-
3f and Stat3 act in concert in the maintenance of the MM
signaling, it is worthwhile considering a more specific strategy that
target Stat3/14-3-3f interaction, as such drugs may spare some of
the essential homeostatic functions executed by 14-3-3f and Stat3
on their own, while inhibiting their malicious cooperation in
Figure 5. 14-3-3f protects Stat3 phosphorylation. (A) Competition of R18 peptide for 14-3-3f/Stat3 interaction. Immunoprecipitated 14-3-3f
from U266 cells transfected with Myc-Stat3 was incubated with varying amounts of R18 and analyzed by Western blotting with the indicated
antibodies. (B) Total cell lysates were prepared in phosphatase lysis buffer A, and aliquots were either left on ice or dephosphorylated in the presence
(+) or absence (2)o f2 5mM R18 peptide. Reactions were analyzed by immunoblotting (IB) with the indicated antibodies. (C) Lysates from U266 cells
were prepared as in A. Aliquots were either left on ice or dephosphorylated in the presence of 25 mM R18 peptide. Where indicated, FST (1–10 mM)
was added on ice for 10 min before initiating dephosphorylation. Reactions were analyzed by Western blotting with the indicated antibodies. (D)
Immunoprecipitated Stat3 from U266 cells was treated with the indicated units of purified PP2A enzyme at 30uC for 30 min, and analyzed by Western
blotting with the indicated antibodies. All experiments were performed in triplicate and representative data are shown.
doi:10.1371/journal.pone.0029554.g005
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with total 14-3-3f or Stat3 inhibition and retain most of their
functions but may affect tumor growth. Taken together, the
malicious cooperation formed by 14-3-3f and Stat3 may serve as
the Achilles Heel of MM and many other cancers, providing new
opportunities for therapeutic intervention. Experiments testing this
hypothesis are ongoing in our laboratory.
Materials and Methods
Materials and Antibodies
The R18 peptide, with a sequence of PHCVPRDLSWL
DLEANMCLP, was purchased from Biomol International (Plym-
outh Meeting, PA). Fostriecin (FST), a selective inhibitor of protein
phosphatase 2A (PP2A) was purchased from Sigma-Aldrich
(Taufkirchen, Germany). The antibodies and sources of the
antibodies used in this study were as follows: 14-3-3f, 14-3-3e,1 4 -
3-3s, 14-3-3h, 14-3-3b, GAPDH antibodies (Santa Cruz Biotech-
nology, Santa Cruz, CA), 14-3-3c, 14-3-3g, Stat3, pY705-Stat3,
pS727-Stat3 antibodies (Cell Signaling, Danvers, MA), HA tag,
Myc tag antibodies (Genecopoeia, Rockville, MD). Antibodies to
PKC isoforms were obtained from BD Biosciences (San Jose, CA).
Cell Cultures
The human myeloma cell line U266 was purchased from
American Type Culture Collections (Rockville, MD). All cells were
routinely maintained in RPMI 1640 supplemented with 1%
penicillin/streptomycin, 1 mmol/L L-glutamine, and 10% fetal
bovine serum at 37uC, 5% CO2 in air. Stable 14-3-3f knock down
(designated as U266-KD) and its negative control (designated as
U266-NC) cell lines were generated and maintained as previously
described [9].
Plasmid Constructs and Transient Transfections
Human Stat3 and its truncated isoforms corresponding to
amino acids 1–688, 1–585, 1–465, 1–320, 1–130 or 688–770 were
cloned into the NH2 terminal Myc-tagged pReceiver-M43
expression vector (Genecopoeia, Rockville, MD). Human 14-3-
3f was cloned into the NH2 terminal HA-tagged pReceiver-M06
expression vector.
To create point mutations in the C terminus of Stat3, the
expression vector encoding C terminus of Stat3 (688–770) was
used as a template. Construction of mutant Stat3 (688–770)
cDNAs, where the codons for S691, T714, T717, S719 and S727
are exchanged to Ala, was performed by site-directed mutagenesis
using a QuikChange kit (Stratagene, La Jolla, CA) following the
manufacturer’s instructions. Primers used, with the introduced
mutations underlined, were: (Ser691RAla) 59-GTCGGCCA-
GAGGCCCAGGAGCAT-39; (Thr714RAla) 59-CTGTGTG-
GCACCAAC GACCTGC-39; (Thr717RAla) 59-GTGA CAC-
CAACGGCCTGCAGCAAT-39; (Ser719RAla) 59- CGACCT-
GCGCCAATA CCATTGAC-39; (Ser727RAla) 59-GACCT-
Figure 6. Proposed model of 14-3-3 and Stat3 interaction. The model illustrated that multiple signaling events, including PKC, Raf1, MEK1/2,
ERK1/2 and PP2A, impinge on Stat3 and that 14-3-3f serves as an essential coordinator for different pathways to regulate Stat3 activity in myeloma
cells.
doi:10.1371/journal.pone.0029554.g006
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confirmed by DNA sequence analysis. The plasmids were
introduced into U266 cells using the Nucleofector X005 (Amaxa,
Cologne, Germany), according to the Optimized Protocol for the
U266B1 cell line.
Immunoprecipitation and Western blot analysis
Protein extracts prepared with lysis buffer (150 mM NaCl,
10 mM HEPES, pH 7.5, 0.2% Nonidet P-40, 5 mM NaF, 5 mM
Na4P2O7, 2 mM Na3VO4, 10 mg/l aprotinin, 10 mg/l leupeptin,
and 1 mM PMSF), incubated on ice for 309, and centrifuged to
remove insoluble materials. The BioRad (Hercules, CA) protein
assay was used to measure protein concentrations. For immuno-
precipitations, cell extract was precleared by Protein A/G Plus
beads (Santa Cruz Biotechnology) followed by incubation with
primary antibody overnight on a rocker at 4uC. Immune complexes
were pulled down by incubating with Protein A/G Plus beads for
4 h at 4uC followed by washing twice with lysis buffer containing
0.1% Triton X-100, and two times with lysis buffer without
detergent. Bound proteins were eluted by boiling and analyzed by
Western blot. For Western blots, 30 mg of cellular extract was
resolved by 10% SDS-PAGE, transferred to nitrocellulose, and
probed with appropriate antibodies. These experiments were
repeated three times and representative data are shown.
Preparation of the structures for MD simulations
The crystal structure of the 14-3-3f/serotonin N-acetyltrans-
ferase complex (PBD ID: 1IB1) was used as the template to
construct the 14-3-3f/Stat3 peptide complex by mutating the
residues on N-acetyltransferase to the corresponding residues of
Stat3, with the phosphorylation residues (S for Stat3 and T for N-
acetyltransferase) for sequence alignment point. After 24 ns
balance with simulations, the pSer727 Stat3 peptide was then
used as a template to construct a dephosphorylated Stat3 peptide.
All the structures were modeled by using the program LEaP
embeded in AMBER10 program with the parm99 AMBER force
field [52]. The protonation states of HIS164 were treated as HID
(ND1-protonated) form. The systems were neutralized and
immersed in octahedral periodic box of TIP3P [53] water
molecules with a closeness parameter of 8 A ˚ away from the
boundary of any atoms. The AMBER force field parameter for
phosphoserine, which were retrieved from the AMBER parameter
database (http://www.pharmacy.manchester.ac.uk/bryce/amber/)
[54,55] were used to build the phosphorylated structure. The 14-3-
3f/pSer727 Stat3 peptide complex system contains 9043 waters and
9N a
+ions with a volume of 361016.092 A ˚ 3 (oct).The 14-3-3f/Stat3
peptidecomplexsystemcontains8640watersand 11 Na
+ionswitha
volume of 349988.538 A ˚ 3 (oct).
MD Simulations
The Ewald method [56] was used for the treatment of long
range electrostatic interactions and the SHAKE algorithm were
used for constraining all bonds involving hydrogen atoms. The
non-bond interaction cutoff was set to 8.0 A ˚. Energy minimization
was performed for each solvated complex using the conjugate
gradient algorithm, harmonic constraints were applied with a force
constant gradually relaxed from 2 kcal/A ˚. After minimization, all
systems were heated up from 0 K to 310 K during 50 ps, then
50 ps density equilibration at 310 K with weak restraints on the
complex (2 kcal/A ˚) was carried out. Production runs were carried
out for more than 24 ns at 310 K. An integration time-step of 2 fs
was used and structures were saved every 4 ps. The systems were
run with constant pressure and temperature (NPT ensemble mode)
with periodic boundary conditions. Constant pressure was
maintained using the Langevin piston method with a 1 kDa
pressure piston, a piston collision frequency of 2 ps-1.
MM-PBSA Calculations and Analysis
The binding free energy was calculated by the MM/PBSA
(Molecular Mechanics/Poisson-Boltzmann Surface Area) [57,58]
method using the MM-PBSA package of the AMBER10 [52,59].
It needs dynamical sampling of the system in explicit water and
also needs to post-process the trajectory of the system from MD
production runs. The binding free energy was calculated by using
a simple thermodynamic cycle that combines the molecular
mechanical and continuum solvent approach PB [60,61]. We get
snapshot every 4 ps from MD trajectory and the binding free
energy was calculated according to the equation [62]:
DGbind~GtotC{GtotA{GtotB ð1Þ
where C, A and B stand for complex, monomer A and monomer B
for sake of representation. The free energy of each species was
calculated ad follows:
G~EMMzGSOL{TDS ð2Þ
where EMM was the molecular mechanics energy, or enthalpic
contribution and were given by internal energy (bonds, angles and
dihedrals) (Eint), electrostatic energy (Eele) and van der waals term
(Evdw):
EMM~EintzEelezEvdw ð3Þ
GSOL denoted the salvation free energy which was composed of
the polar and nonpolar part. The polar part is the electrostatic
contribution to solvation which calculated by solving the linear
Poisson Boltzmann equation in a continuum model of the solvent.
The nonpolar part accounts for the cost of opening a cavity in the
condensed phase, which is related linearly to the solvent accessible
surface area [63]. GSOL was calculated according to the equation
in AMBER10. TDS is omitted since for both 14-3-3f/pSer727
Stat3 peptide and 14-3-3f/Stat3 peptide, the TDS of them are
similar.
Immunocytochemistry
The U266 and U266-KD cells were grown on sterile glass
coverslips using 24-well plates coated with poly-l-lysine (Sigma,
USA) and then fixed with 4% paraformaldehyde, permeabilized
by 0.1% Triton X- 100. After a brief washing in PBS, slides were
blocked with 5% bovine serum albumin for 1 h and then
incubated with the anti-Stat3 at a dilution of 1:500. The cells
were then washed three times with PBS and incubated with Texas
red-conjugated secondary antibody (Santa Cruz Biotechnology) at
a dilution of 1:500 for 1 h. Finally, the cells were washed with PBS
followed by incubation with Hoechst (50 ng/mL) for 15 min and
then thoroughly washed again with PBS. The coverslips with
stained cells were mounted on glass slides with anti-fade mounting
medium and viewed under a fluorescence-microscope (Nikon,
Japan). Pictures were captured using a Photometrics Coolsnap CF
color camera (Nikon). Experiments were performed in triplicate
and representative data are shown.
Stat3 Luciferase Reporter Assay
U266, U266-NC or U266-KD cells were transfectedwitha blank
or HA-14-3-3f plasmid, and a Stat3 firefly luciferase reporter
plasmid pStat3-TA-luc (Clontech, Mountain View, CA) and a
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3:1.5:0.5 ratio using the Nucleofector X005 (Amaxa, Cologne,
Germany), according to the protocol described above. 48 hours
after transfection, the luciferase activity was determined using a
Dual-Luciferase Reporter Assay kit (Promega, Madison, WI)
according to the manufacturer’s protocol. Experiments were
performed in triplicate. Luciferase values were normalized by
transfection efficiency as measured by b-galactosidase. All data
represent mean values 6 s.d. of three independent experiments.
Electrophoretic Mobility Shift Assay (EMSA) for Stat3-
DNA Binding
U266, U266-NC or U266-KD cells were pelleted and washed
twice in ice-cold PBS. Nuclear protein extracts were prepared with
a nuclear extract kit (Active Motif, Carlsbad, CA) and Stat3-DNA
binding activities were assessed by chemiluminescent electropho-
retic mobility shift analysis (EMSA) Kit (Pierce, Rockford, IL),
according to the manufacturer’s protocol. Briefly, nuclear protein
extracts (10 mg) were incubated in a final volume of 20 mLo f1 0 6
binding buffer, 50% Glycerol, 100 mM MgCl2, 1 mg/mL Poly
(dIdC), 1% NP-40 with the biotin end-labeled high-affinity
sis-inducible element (hSIE) probe (59-CTTCATTTCCCG-
TAAATCCCTAAAGCT- 39) derived from the c-fos gene
promoter, as described [33,34] for 30 min at RT and terminated
by adding 2.0 mLo f1 0 6loading buffer (0.2% (w/v) bromophenol
blue and 0.2% xylene cyanol containing 10% (v/v) glycerol).
Assays were loaded onto native 5% polyacrylamide gels that were
pre-electrophoresed for 60 mins in 0.56 Tris borate/EDTA
buffer, resolved at 100 V, and transferred onto nylon membranes
(Hybond
TM-N+, Amersham) in 0.56Tris borate/EDTA buffer at
100 V for 30 mins. DNA was cross-linked (120 mJ/cm
2) and
detected using HRP-conjugated streptavidin chemiluminescence.
For competition assays, nuclear extracts containing equal amounts
of total protein were incubated with 100-fold molar excess of
unlabeled hSIE probe. The immunoblots were scanned, and
densitometric analysis was performed using the public domain
NIH Image program ImageJ (developed at the U.S. National
Institutes of Health and available on the Internet at http://rsb.
info.nih.gov/nih-image/). This experiment was repeated three
times and representative data are shown.
Measurement of PKC Activity
PKC activity was determined in PKC immunoprecipitate using a
PKC assay kit (Millipore, Billerica, MA) according to the
manufacturer’s instructions. The assay kit is based on phosphory-
lation of a specific substrate peptide (QKRPSQRSKYL) using the
transfer of the c-phosphate of adenosine-59-[
32P] triphosphate
([c-
32P] ATP) by PKC kinase. The phosphorylated substrate is then
separated from the residual [c-
32P] ATP using P81 phosphocellulose
paper and quantitated by using a Beckman LS 6500 scintillation
counter (Brea, CA). Endogenous phosphorylation of proteins in the
sample was determined by substituting the assay dilution buffer for
the substrate mixture. To assure that equal amounts of PKC were
used in the assay, immunoprecipitates were denaturated, eluted,
separated by 10% SDS-PAGE, electrophoretically transferred, and
immunoblotted with PKC antibody. This experiment was repeated
three times and representative data are shown.
In Vitro Stat3 Dephosphorylation Assay
U266 cells transiently transfected with Myc-Stat3 were washed
twice with PBS. Cell extracts were prepared in phosphatase assay
buffer A (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1 mM EDTA,
0.25% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride,
10 mg/ml aprotinin, and 10 mg/ml leupeptin, which was also
supplemented with one tablet of serine and cysteine protease
inhibitor per 10 ml of buffer). The buffer lacked serine/threonine
phosphatase inhibitors, and the cell extracts were maintained on
ice. Extracts were cleared of cellular debris by centrifugation at
14,0006 g for 5 min at 4uC. For competition assay, aliquots of
clarified lysates containing equal amounts of protein were
immunoprecipitated with anti-Myc antibody as described above
and incubated with various concentrations of R18 peptide for
60 min on ice. For dephosphorylation assay, aliquots of lysates
were incubated either with or without 25 mM R18 peptide. Where
indicated, FST was added to the appropriate aliquots on ice for
10 min before initiation of dephosphorylation. Dephosphorylation
was performed by incubating lysates for 30 min at 30uC with
intermittent mixing before terminating the reaction by boiling in
46Laemmli reducing sample buffer. For dephosphorylation of
Stat3 by PP2A, four aliquots of RIPA buffer (50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1% [V/V] NP-40, 0.5% [W/V] sodium
deoxycholate, 0.1% [W/V] SDS, and 5 mM EDTA) extracts from
U266 cells transfected with Myc-Stat3, equalized for protein
concentration and volume, were subjected to immunoprecipitation
with anti-Myc antibody. Three of the anti-Myc immunocomplexes
containing Stat3 were resuspended in phosphatase lysis buffer B
[20 mM 3-(N-morpholino)propanesulfonic acid, pH 7.5, 150 mM
NaCl, and 14.4 mM b-mercaptoethanol] supplemented with
Complete (Roche, Indianapolis, IN) but no phosphatase inhibitors
and subjected to treatment with the indicated units of purified
PP2A purified enzyme (Upstate, Temecula, CA) for 30 min at
30uC with intermittent mixing. The remaining immunocomplex
was incubated in phosphatase lysis buffer B alone. The reactions
were terminated by boiling in 46Laemmli reducing sample buffer.
The proteins were resolved by SDS-PAGE and then immuno-
blotted with the appropriate antibodies. This experiment was
repeated three times and representative data are shown.
Statistical Analysis
Data are expressed as the mean 6 standard error of the mean
from at least three separate experiments performed in triplicate,
unless otherwise noted. Statistical analysis was performed using a
two-tailed Student’s t-test. Results were considered significant if p
values were less than 0.05.
Supporting Information
Table S1 Sequences of 14-3-3f interaction peptides in
Protein Data Bank. Red letter stands for the residue
which interacts with phosphorylated residue (blue
letter).
(DOC)
Video S1 The movements of 14-3-3f (cyan), the Ser727
phosphorylated STAT3 peptide (purple) and the dephos-
phorylated STAT3 peptide (green) during MD simula-
tions were shown in the movie. As shown in the video, the
dephosphorylated STAT3 peptide moves away from the binding
region and the residue pSer727 of phosphorylated STAT3 peptide
forms four stable salt bridges with R56, R60, R127 of 14-3-3f and
with R729 of phosphorylated Stat3 peptide itself.
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